PR Newswire BiotechOriginal article
/C O R R E C T I O N - Pierre Fabre Pharmaceuticals/
BLA FilingTabelecleucelPositive
AI Analysis
Summary
Pierre Fabre Pharmaceuticals announced FDA acceptance of a BLA resubmission for Tabelecleucel for the treatment of Epstein-Barr Virus-positive post-transplant lymphoproliferative disease. The acceptance of the resubmission represents progress toward potential regulatory approval.
Outcome Details
FDA accepted BLA resubmission
Importance:7/10
Sentiment:
0.70
FDABLAResubmissionRegulatoryCell therapy
Read the original article
Published by PR Newswire Biotech on October 14, 2026 1:32 PM